Raptor acquires fluoroquinolone antibiotic Quinsair from Tripex
Quinsair is an inhaled formulation of levofloxacin, which already received approval in the European Union and Canada. It is used to manage chronic pulmonary infections due to Pseudomonas
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.